Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and oral etoposide in platinum-resistant ovarian cancer
NCT04217798Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04217798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04217798.